Clinical staging systems use physical examination and blood count results to provide prognostic information. Various biological and genetic markers provide additional prognostic information. Short-arm deletions of chromosome 17 (del[17p]) and or mutations in the TP53 gene predict resistance to chemoimmunotherapy and shortened time to progression with most targeted therapies. The CLL International Prognostic Index integrates genetic, biological and clinical variables to identify different risk groups of CLL patients.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
